Studies the Ion endoluminal system in people with lung nodules or lung cancer
Collects real-world data on the Ion device used to examine lung nodules.
Plain-language title generated from the registry record
Registry title: European Real-World Registry for Use of the Ion Endoluminal System
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- Universitätsspital ZürichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Intuitive Surgical
- Trial code
- NCT06923774
- Record updated
- 9 October 2026
- Original description
The objective of this study is to collect collect real-world data for the Ion endoluminal system.Read full original descriptionShow less
A European Multi-Center, Prospective, Single-Arm, Observational Study to Evaluate Real-World Outcomes for the Ion Endoluminal System
The objective of this study is to collect collect real-world data for the Ion endoluminal system.
Inclusion: Patient is aged 18 years or older at time of consent; Patient is planned to undergo a lung lesion biopsy(s) and/or localization procedure(s) utilizing the Ion endoluminal system; Patient is willing and able to give written informed consent for clinical study participation.
Exclusion: Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results; Female patient that is pregnant or breast feeding as determined by standard site practices; Patient is legally incapacitated or in a legal/court ordered institution or is part of a known vulnerable population, including but not limited to dependency on the sponsor, hospital or study doctor; Patient is not willing to comply with post-procedure study participation requirements; Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the clinical study.